Response and Tolerability of Palbociclib Plus Fulvestrant in Breast Cancer Patient with Bone Marrow Metastasis and Cytopenia: A Case Report


MUTLU E., ÖZKAN M., FIRAT S. T., COŞAR R.

ERCIYES MEDICAL JOURNAL, vol.45, no.1, pp.101-103, 2023 (ESCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 45 Issue: 1
  • Publication Date: 2023
  • Doi Number: 10.14744/etd.2022.21043
  • Journal Name: ERCIYES MEDICAL JOURNAL
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Academic Search Premier, CAB Abstracts, EMBASE, Veterinary Science Database, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.101-103
  • Erciyes University Affiliated: Yes

Abstract

Background: Palbociclib is a potent cyclin-dependent kinase (CDK) 4/6 inhibitor that impairs cell cycle progression. It has recently been approved for patients with hormone receptor positive metastatic breast cancer.Case Report: We report the response achieved palbociclib plus fulvestrant therapy in a 68-year-old female breast cancer patient with bone marrow metastasis. She treated with paclitaxel weekly chemotherapy, but no response was obtained. Then, with dose reduction palbociclib 75 mg/day, plus fulvestrant treatment was administered. After 6 cycles, thrombocyto-penia resolved and the palbociclib dose was increased to 125 mg/day. Cytopenia completely resolved after the eight cycle treatments. She is still going on treatment without progression and side effects.Conclusion: The efficacy and safety of CDK 4/6 inhibitors in patients with bone marrow metastases have not been clarified. However, palbociclib treatment can be given with close follow-up and dose reduction in breast cancer patients with bone marrow metastasis.